Lease obligation, current               145,210        150,095 
   Accrued expenses and other 
    current liabilities                  2,161,374      2,259,955 
   Insurance premium financing 
    payable                                 71,662        381,784 
                                       -----------    ----------- 
      Total current liabilities          4,907,466      3,438,601 
   Lease obligation, net of current 
    portion                                     --         90,124 
                                                      ----------- 
      Total liabilities                  4,907,466      3,528,725 
                                       -----------    ----------- 
Commitments and contingencies (see 
Note 13) 
Stockholders' equity: 
Preferred stock, $0.001 par value; 
10,000,000 shares authorized; 0 
shares issued and outstanding at 
September 30, 2024 and December 31, 
2023                                            --             -- 
Common stock, $0.001 par value; 
 100,000,000 shares authorized; 
 7,464,070 and 6,186,280 shares 
 issued and outstanding at September 
 30, 2024 and December 31, 2023              7,464          6,186 
Additional paid-in capital              81,748,225     77,871,584 
Accumulated other comprehensive 
 (loss) income                               1,754            877 
Accumulated deficit                    (82,288,034)   (66,900,725) 
                                       -----------    ----------- 
   Total stockholders' equity             (530,591)    10,977,922 
                                       -----------    ----------- 
      Total liabilities and 
       stockholders' (deficit) 
       equity                         $  4,376,875   $ 14,506,647 
 
 
 
 
                        Inhibikase Therapeutics, Inc. 
              Condensed Consolidated Statements of Operations and 
                              Comprehensive Loss 
                                  (Unaudited) 
 
                        Three Months Ended       Nine Months Ended September 
                          September 30,                      30, 
                    --------------------------  ------------------------------ 
                        2024          2023          2024           2023 
Revenue: 
   Grant revenue    $        --   $    79,569   $         --   $    260,500 
                     ----------    ----------    -----------    ----------- 
Total revenue                --        79,569             --        260,500 
                     ----------    ----------    -----------    ----------- 
Costs and 
expenses: 
   Research and 
    development       4,189,873     3,225,551     10,016,982     10,615,368 
   Selling, 
    general and 
    administrative    1,637,603     1,622,894      5,643,386      5,331,358 
                     ----------    ----------    -----------    ----------- 
Total costs and 
 expenses             5,827,476     4,848,445     15,660,368     15,946,726 
                     ----------    ----------    -----------    ----------- 
Loss from 
 operations          (5,827,476)   (4,768,876)   (15,660,368)   (15,686,226) 
Interest income 
 (expense)               49,410       173,677        273,059        835,283 
                     ----------    ----------    -----------    ----------- 
 
Net loss             (5,778,066)   (4,595,199)   (15,387,309)   (14,850,943) 
Other 
comprehensive 
loss, net of tax 
   Unrealized 
    gains (loss) 
    on marketable 
    securities            2,778         1,571            877       (104,861) 
                     ----------    ----------    -----------    ----------- 
Comprehensive Loss  $(5,775,288)  $(4,593,628)  $(15,386,432)  $(14,955,804) 
                     ----------    ----------    -----------    ----------- 
Net loss per share 
 -- basic and 
 diluted            $     (0.65)  $     (0.75)  $      (2.03)  $      (2.48) 
                     ==========    ==========    ===========    =========== 
Weighted-average 
 number of common 
 shares -- basic 
 and diluted          8,882,570     6,162,671      7,592,103      5,977,841 
                     ==========    ==========    ===========    =========== 
 

(END) Dow Jones Newswires

November 14, 2024 08:37 ET (13:37 GMT)